Depression and anxiety are common disorders in youth that can have profound influences on functioning and even mortality. In the late 1990s, large controlled trials began demonstrating the efficacy of selective serotonin reuptake inhibitors for these conditions in the pediatric population. By 2003, regulatory agencies began warning the public of unrecognized risk and misrepresented benefit. The current review article summarizes a series of published and unpublished efficacy and safety data regarding antidepressant use in children and adolescents. The resulting complex synthesis suggests that these medications may offer mild-to-moderate benefit, with notable exceptions depending on medication and indication, but they may also heighten the risk for suicidal ideation and parasuicidal behavior. However, reviewed epidemiological data does not demonstrate a relationship between newer antidepressant prescription and completed suicide in large populations of youth. In conclusion, this breadth of mixed research data is applied to clinical decision making.
Introduction
Depressive and anxiety disorders are quite common in youth. Antidepressant medications have increasingly been used to treat these conditions in children and adolescents, but controversies have arisen around the efficacy and safety of these medications. This article will review the prevalence of depression and anxiety in children and adolescents, the efficacy data regarding antidepressant trials in youth, the safety data regarding antidepressant trials in children and adolescents, and then discuss the implications of this literature in approaching treatment decisions in youth.
Prevalence of depression and anxiety in children and adolescents
Both depressive disorders and anxiety disorders are very common in youth and are often comorbid with one another. Anxiety disorders are the most frequent cluster of psychiatric illnesses diagnosed in children. The point prevalence has been estimated between 6 and 20%. 1 Anxiety problems are often chronic and/or recurrent in nature and frequently precede depressive illnesses. Roughly one-fifth of adolescents have at least one episode of clinical depression before the age of 18 and nearly two-thirds of adolescents report depressive symptoms that are less severe or briefer in nature. 2 The average duration of a depressive episode in youth is 7-9 months, and the rate of recurrence within 5 years can be as high as 70%. 3 Both depressive disorders and anxiety disorders can have profound influences on social and academic function. In addition, suicide is the third leading cause of death 4, 5 in adolescents in the United States and depressive disorders in particular are a risk factor for suicide. Nearly 20% of adolescents in the general population endorse suicidal ideation in the past year, with higher rates reported for youth with depressive illnesses. 6 In 2006 in the United States, 2801 youth between 10 and 21 years of age died by suicide. 7 In 2007, 14.5% of high school students reported seriously considering a suicide attempt in the year before, and 6.9% of high school students reported that they had actually attempted suicide at least once in that time period. 8 
Efficacy of treatments for depression and anxiety in children and adolescents
As depressive disorders and anxiety disorders are so common and have been associated with considerable morbidity and mortality, it is not surprising that providers have sought effective treatments for children and adolescents with anxiety and depression for decades.
Multiple controlled trials since the late 1990s have demonstrated that cognitive-behavioral therapy (CBT) is effective for the treatment of anxiety disorders and that either CBT or interpersonal therapy is effective for the treatment of depression in youth. Unfortunately, there are limited psychotherapy resources available for children and adolescents, and these treatments can be time and effort-intensive on the part of youth and families. In addition, the majority of providers who treat youth have not been trained in evidence-based psychotherapeutic interventions. Since most youth with depression are unable either to find a trained therapist, participate regularly in a structured treatment, or navigate the complicated systems of care required to access psychotherapy, these treatment interventions are often ultimately unavailable to the youth who need them. There have also been concerns that the most affected youth may be unable to effectively engage in psychotherapy because of the behavioral and cognitive ramifications of their illness. Consequently, many providers have long sought medication interventions to address anxiety and depressive disorders in youth.
Before the late 1990s, the antidepressant medications commonly used for adults, (tricyclic antidepressants and monoamine oxidase inhibitors) had no demonstrated efficacy in depressed youth, and only modest support for anxious youth, despite a number of clinical trials of these medications. In addition, these older medications posed substantial safety risks. In 1997, the selective serotonin reuptake inhibitor (SSRI), fluoxetine, was shown to be effective in a large, randomized, double-blind, placebo-controlled trial (RDBPCT) in 96 depressed youth. 9 Several subsequent studies of SSRIs showed some efficacy in treating depression and anxiety in children and adolescents. In the ensuing years, SSRI prescriptions for youth in the United States rose dramatically. By 2003, large RDBPCTs had been conducted with fluoxetine and sertraline demonstrating some efficacy in depressed youth. 10, 11 Similarly, by 2003, large RDBPCTs had shown some benefit from sertraline, fluoxetine and fluvoxamine in anxiety disorders in children and adolescents. [12] [13] [14] In 2003, however, as regulatory agencies in the Great Britain, the United States and elsewhere reviewed the data for SSRIs in children and adolescents, concern arose that the published data exaggerated or misrepresented the efficacy of these medications, had not recognized the potential risks of these medications and/or had omitted relevant information from unpublished studies. By June 2003, the UK Department of Health warned against using paroxetine in youth 15 and in December 2003 warned against prescribing any SSRI except fluoxetine in this population because of these concerns. 16 In March 2004, the US Food and Drug Administration issued a Public Health Advisory regarding antidepressant use in adults and children 17 and in October 2004 mandated labeling changes for these medications to include a black box warning regarding the risk of inducing suicidality in youth. 18 European, Canadian and Australian regulators issued warning statements in this period as well.
19-21 Reviews and hearings since that time have incorporated information from both published and unpublished studies of antidepressant medications in youth.
Perhaps the single most informative study regarding the efficacy of an antidepressant medication for the treatment of depression in adolescents was the Treatment for Adolescents with Depression Study. 22 This 12-week-RDBPCT involved the randomization of 439 patients between 12 and 17 years old to four treatment conditions: placebo, fluoxetine alone, CBT alone or fluoxetine with CBT. Ultimately, on one of the two primary outcome measures (clinician total score on the Children's Depression Rating ScaleRevised, CDRS-R) compared with placebo, the combination treatment was statistically superior in efficacy, whereas neither intervention alone was statistically superior to placebo. Interestingly, although neither intervention alone distinguished itself from placebo, fluoxetine alone did show superior efficacy relative to CBT alone. On the second primary outcome measure, end-of-treatment Clinical Global Impression (CGI) score, combined treatment and fluoxetine alone were statistically superior to placebo and CBT alone, while CBT alone was not statistically superior to placebo. After the initial 12-week-period, the TADS study was continued unblinded with 327 of the patients who had been in active treatment arms for 36 weeks without a placebo comparison group. 23 By the conclusion of this long-term follow-up period, the response rate on the CDRS-R for combination therapy was 86%, the response rate for fluoxetine alone was 81% and the response rate for CBT alone was 81%. This convergence of response rates for all three active treatments suggests that fluoxetine, either alone or in combination with CBT, may have accelerated the response to treatment, but that over time all three showed similar effectiveness.
In examining other individual studies regarding antidepressants in depressed youth, the data are not consistent. Although two other large studies (in addition to TADS) also indicated efficacy from fluoxetine in depressed youth, 9,10 the studies with other SSRIs have not been as clear. Two multicenter RDBPCTs were merged to generate the data for one large study of sertraline in depressed children and adolescents. 11 In this study, 376 depressed youth, aged 6-17 years, were randomized to either sertraline or placebo for 10 weeks. A statistically significant benefit from sertraline was noted on the CDRS-R, but the clinical significance of the change was difficult to interpret (CDRS-R decrease of 22.84 with sertraline compared with a decrease of 20.19 with placebo). Similarly, in an 8-week-RDBPCT of citalopram with 174 depressed youth ages 7-17 years, there was statistical significance reported in the improvement on the primary outcome measure (also the CDRS-R) but the clinical significance was unclear. 24 A European, multicenter RDBPCT of citalopram in 244 depressed adolescents did not demonstrate benefit from the active medication. 25 A pair of studies involving paroxetine also had conflicting results. 26, 27 An 8-week-RDBCT of escitalopram with 264 patients ages 6-17 years did not show significant improvement on the primary outcome measure (also the CDRS-R) in the total study, but in the post-hoc analysis, the adolescent subgroup was noted to have significant improvement on this measure if observed cases of completers were used for the analysis, but not for the last observations carried forward. 28 With regard to treatment-resistant depression, the 2008 TORDIA study analyzed response to treatment after a failed trial of an SSRI in 334 youth between 12 and 18 years old. 29 They were randomized to four potential treatment groups: switching to an alternative SSRI alone, switching to an alternative SSRI with CBT, switching to venlafaxine alone or switching to venlafaxine with CBT. This study used a decrease of at least 50% on the CDRS-R, the change in CDRS over time and a CGI Improvement subscale score of 2 or less as the primary outcome measures. This study showed that augmentation with CBT with either medication was more effective than either medication alone and there was no difference noted in response between the two medications.
The data for using SSRIs to treat obsessive-compulsive disorder (OCD) and other anxiety disorders in children have been somewhat more promising. Perhaps the single best study of SSRIs in OCD was the Pediatric OCD Treatment Study. 30 In this 12-weekstudy, 112 youth with OCD, ages 7-17 years, were randomized to four treatment conditions: placebo, sertraline alone, cognitive-behavioral therapy (CBT) alone or sertraline with CBT. The primary outcome measure was change on the Children's Yale-Brown Obsessive-Compulsive Scale. All three active treatments were superior to placebo and the combined treatment outperformed either active treatment alone. Other large studies of SSRIs in OCD and other anxiety disorders have found similar benefit. 13, 14, [31] [32] [33] [34] In a meta-analysis of 27, published and unpublished, randomized, placebo-controlled trials of second-generation antidepressants (SSRIs, nefazodone, venlafaxine and mirtazapine) with youth diagnosed with either major depression or anxiety disorders, 35 the authors found evidence of benefit for antidepressant medications for these indications. More specifically, they concluded the evidence was strongest for non-obsessive-compulsive anxiety disorders (number needed to treat = 3), intermediate for OCD (number needed to treat = 6) and weakest for major depressive disorder (number needed to treat = 10). The American College of Neuropsychopharmacology (ACNP) Task Force reviewed the results of 16 clinical trials to consider the efficacy of SSRIs and newer antidepressants (nefazodone, venlafaxine and mirtazapine) in the treatment of major depression in youth. 36 They noted that SSRIs showed trends for efficacy across studies (that is, outperformed placebo on seven of eight studies when dichotomous primary outcome measures were used, outperformed placebo in four of five studies when continuous primary outcome measures were used, and in all seven studies using the CGI), but that these results were often not statistically significant and appeared confounded by high placebo responses. This ACNP task force analysis highlighted how many studies showed the antidepressants did not separate from placebo on the primary outcome variables chosen, suggesting that while antidepressants, particularly SSRIs, may show some benefit for treating depression, the degree of benefit may be modest.
Safety of treatments for depression and anxiety in children and adolescents
The primary safety issue for antidepressant medications in youth pertains to mood-related adverse effects. In general, the somatic side effects of second-generation antidepressants are mild and include gastrointestinal upset, headaches, sedation and insomnia. In contrast to the potential cardiac toxicity and lethality in overdose of older tricyclic antidepressants, these newer medications often seem reassuring. However, the emotional and behavioral side effects of antidepressants, such as agitation, hostility, hypomania and suicidal ideation, have been the focus of substantial concern. Assessing the safety of antidepressant medications in youth is complicated by multiple variables including the fact that suicide-related events are infrequent, so very large sample sizes would be required to detect small differences between treatment groups. It should be noted that no youth under 18 years of age completed suicide in any of the RDBPCTs completed to date. In addition, most controlled medication trials excluded those youth with known suicidality and the early studies often did not systematically assess for suicidal ideation or parasuicidal actions. The Treatment for Adolescents with Depression Study 22 did actively assess for suicidal ideation and psychiatric adverse effects as part of the investigation. Roughly 30% of the adolescents in the study endorsed some experience of suicidality at the onset of the study, thus allowing for some prospective analysis of antidepressant treatment on suicidal ideation and parasuicidal behavior. After 12 weeks, all four groups in the study (medication alone, cognitive-behavioral therapy alone, combined treatment and placebo) experienced a decrease from the baseline reported level of suicidal thinking. The greatest decrease was experienced in the combined treatment group and the least improvement in suicidality was noted in the medication only group, suggesting that cognitive-behavioral therapy may have been protective in this regard. An emergence or worsening of suicide-related behaviors was noted in 4.8% of all subjects (18/374) on the Suicidal Ideation Questionnaire: Grades 7-9 (SIQ-Jr). For the fluoxetine alone arm of the study, 7.3% had an emergence or worsening of suicide-related behaviors on the SIQ-Jr, compared with 7.6% in the placebo arm, 2.2% in the CBT alone arm and 2.2% in the combined treatment arm, again raising the possibility that CBT was protective against suicidality.
Three meta-analyses have examined suicidality in youth treated with antidepressant medication. 35, 37, 38 The Hammad and Bridge analyses 35, 38 both included RDBPCTs of antidepressant medications in youth for depression and anxiety disorders. The Hammad analysis 38 also included one trial of the antidepressant bupropion for attention-deficit hyperactivity disorder, whereas the Bridge analysis 35 focused only on second-generation antidepressants in the treatment of depression or anxiety disorders. The Bridge analysis had a larger number of studies examined because of the later publication date. The Whittington analysis 37 focused solely on the treatment of depression and had the smallest number of studies included. All three analyses concluded that there is some risk of increased mood-related side effects, including suicide attempts, in the treatment of youth with antidepressant medications. The Bridge study calculated the number needed to harm for treatment of depression in youth was 112, the number needed to harm for treatment of OCD in youth was 200 and the number needed to harm for treatment of other anxiety in children and adolescents was 143. This Bridge analysis estimated the relative risk of suicidal ideation/attempts for antidepressant treatment as lower than the risk reported by Hammad. The Hammad and Whittington analyses used a fixed effects approach to analyzing the data, whereas the Bridge analysis used a random effects approach, which may explain this difference in interpreting the data, since the fixed effects approach is less conservative.
The following Table 1 , assembled from the Bridge analysis, summarizes the 27 studies and the authors' calculations of the quality, efficacy and risk of suicide ideation/attempts based on the data available for each study and for each medication (where multiple studies examined a single medication for the same indication).
Additional information in considering the safety of antidepressant medications in youth: toxicology studies and epidemiology studies Two studies of youth suicides 51, 52 analyzed for antidepressant use in completed suicides. In the Gray study, 51 while nearly a quarter of the youth who died by suicide had been prescribed antidepressants, none had toxicological indicators of selective serotonin reuptake use at the time of their death. In the Leon study, 52 roughly 10% tested positive for antidepressants (half were SSRIs, the other half tricyclic antidepressants), indicating the vast majority of completed youth suicides were not treated with this class of medication at the time of their suicide.
Investigators have noted that those countries with the highest prescription rates of SSRIs in that window of time had the lowest suicide rates and the greatest declines in rates. 53, 54 At least three countries have specifically noted an association between decreasing suicide rates in youth and increasing prescription rates: Sweden, Finland and the United States. [55] [56] [57] According to the Centers for Disease Control, completed suicides in the United States in those ages 10-19 years rose in 2004, compared with the rate in 2003, which corresponded to a decrease in the rate of SSRI prescriptions following the Food and Drug Administration's Black Box Warning regarding these medications. 58 A nearly 50% increase in the suicide rate of youth was noted in the Netherlands between 2003 and 2005 (from 0.86 per 100 000 to 1.28 per 100 000), corresponding to a decrease in SSRI prescriptions by over 20%. 59 In that same analysis, a 14% increase in the suicide rate of US youth was noted from 2003 to 2004 (from 2.83 per 100 000 to 3.23 per 100 000) following the black box warning for antidepressants. A similar association was noted in Canada, with the rate of completed suicides in youth increasing from 0.04 per 1000 before the warning to 0.15 per 1000 after the warning, coincident with a 14% decrease in the rate of antidepressant prescriptions to this population. 60 Of course multiple variables may influence suicide rates and prescription rates, so causality can not be presumed based on these studies.
Conclusion
Depression and anxiety are common problems in youth, which result in significant morbidity and mortality. Although psychotherapeutic interventions offer significant benefits for many children and adolescents with these conditions, evidence-based psychotherapy interventions are difficult to access and many youth go untreated for a variety of reasons. The emergence of data regarding newer antidepressant medications in the late 1990s, showed some degree of efficacy for pharmacological treatments in this population and stimulated an increase in prescriptions for youth with these serious conditions. Subsequent analysis of the published and unpublished data that emerged in the following years revealed a complex scenario, suggesting that antidepressants may offer mild-tomoderate benefits, but may also heighten the risk for suicidal ideation and parasuicidal action in this population. This analysis is far from straightforward, however, as epidemiological data would suggest that rates of completed suicide actually decreased as the rates of prescription of newer antidepressants increased and data from completed suicides do not show evidence of linkage between newer antidepressant use and completed suicide. Concerns also arose regarding the quality of the studies and the transparency of the information produced, since pharmaceutical companies appeared to show bias in their initial decisions to publish these trials. Also, there were discrepancies between the results of primary and secondary outcome measures in these studies and there were external incentives for these companies to produce studies involving children and adolescents quickly, sometimes at the expense of the quality of the study. Last, it should be remembered that antidepressant trials in youth have been notorious for showing high placebo response rates, making it more challenging to demonstrate efficacy from medications, particularly in short-term studies.
In trying to synthesize the information available at this time, several factors should be taken into consideration in deciding how to proceed in treatment with any individual. It does appear that SSRIs can offer some benefit to youth with depression, OCD or other anxiety syndromes. The data for fluoxetine appear to be strongest at this point in time. Nevertheless, since alternative effective treatments are Abbreviations: Dep, major depressive disorder; GAD, generalized anxiety disorder; Med, medication; ND, not determined; OCD, obsessive compulsive disorder; Sep Anx, separation anxiety disorder; SP, social phobia. Quality calculation was based on adequacy of randomization, study entry criteria, outcome measures, therapeutic and placebo procedures, and statistical analyses. Individual items were summed and divided by the total number of applicable items to produce a total score ranging from 0 to 1, where higher scores denote grater methodological quality. To provide common comparisons between the various studies in terms of a scalar measure of efficacy, the authors computed Hedges' g for the dichotomous response variable of each study by means of transformation from the original log odds ratio scale to the standardized mean difference and then from this difference to g. The risk difference was calculated based on the difference in rates of suicidal ideation/suicide attempt/preparatory actions between the treatment group compared with the placebo group. Data for this table along with statistical explanation was obtained with permission from the Bridge et al.
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Efficacy and safety of antidepressant drug treatment A Henry et al available, the potential benefits and risks of medication treatment should be evaluated carefully for each young person. The quality and availability of psychotherapeutic interventions is often highly salient, as well as the individual's attitude toward psychotherapy and past experiences with psychotherapy. For those youth who have ready access to psychotherapy and are open and motivated to engage in therapy, the potential risks of medication may be avoided. Another consideration is the severity of the illness and whether self-harm and/or suicidality has already emerged as part of the underlying condition. For those youth with severe and debilitating depression who are already struggling with suicidal ideation and wish to pursue pharmacological interventions, the risk of augmenting psychotherapy with medication treatment is likely justified in situations where adequate safety plans and close follow-up can be ensured. At this point, there is some suggestion that the diagnosis may also influence the decision to prescribe, as OCD and other anxiety disorders may be more likely to show benefit from these medications with less risk for serious adverse effects than depression. The age of the youth may be another variable to consider, particularly if there appear to be environmental influences highly contributing to the presentation of a younger child suggesting less role for medications and more need for comprehensive psychotherapy treatment. Other potential considerations could include family history of psychiatric illnesses (not only depression and anxiety disorders but also bipolar disorder) and family history of response to medication. Obviously, the decision to pursue medication treatment in a child or adolescent with depression or anxiety is complex and needs to be thoughtfully considered and individualized to the situation of each person. It does appear, however, that antidepressant medications may offer some benefit to youth and prescribers should continue to discuss the potential benefits and risks with children and adolescents and their families as part of the treatment planning process.
